Diverticulitis Disease Treatment Market is Segmented By Type (Diverticulosis, Diverticulitis, Others), By Treatment (Medication, Surgery, Dietary Fiber, Others), By Route of Administration (Oral, Intravenous), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
Diverticulitis Disease Treatment Market is estimated to reach at a CAGR of 7.7% during the forecast period (2024-2031).
Diverticulitis is the infection or inflammation of pouches that occurs in the intestines. These pouches aren't usually harmless. They might appear in the intestines at any time. Diverticulosis is the medical term for having them. Mild diverticulitis can be treated with rest, changes in your diet and antibiotics. Severe or recurring diverticulitis may require surgery.
Diverticulitis Disease Treatment Market Dynamics
New guidelines for treating uncomplicated acute diverticulitis are expected to drive market growth.
Nonantibiotic therapy is currently considered a valid technique for uncomplicated acute diverticulitis by recent guidelines from associations worldwide, including the American Society of Colorectal Surgeons. CT scan findings must be compatible with uncomplicated acute diverticulitis, and patients must not show signs of sepsis, according to clinical practice guidelines for the treatment of left-sided colonic diverticulitis (2020), the Second International Symposium on Diverticular Disease, held in Rome in 2016, and the 2020 WSES guidelines. Immunocompetent patients with simple diverticulitis who show no symptoms of systemic inflammation should not be treated with antibiotics, according to the WSES. Thus, the market is expected to drive in the forecast period from the above statements.
COVID-19 Impact Analysis
The COVID-19 pandemic has moderately impacted healthcare systems and the market. Patients delayed critical therapy for diverticulitis during the early stages of the COVID-19 epidemic, resulting in more severe disease and death. During the early surge, patients who needed surgery urgently/emergently had extreme conditions and stayed longer than expected. Patients who had their planned procedures postponed were more likely to be readmitted to the hospital and require urgent or emergency surgery. Therefore, understanding the impact of COVID-19's early surgeon diverticulitis outcomes may help us better prepare for future surges, improve outcomes, and identify patients who may be able to avoid surgery. Thus, the above statements affected the market, which is expected to boost in the forecast period.
Diverticulitis Disease Treatment Market Segment Analysis
Medication segment is expected to hold the largest market share in diverticulitis disease treatment market
The medication segment is expected to dominate in 2021. The segment is further sub-segmented into antibiotic dugs. Besides, the segment benefits because antibiotics are utilized to treat infections that can occur in acute diverticulitis. For instance, Metronidazole (Flagyl), Trimethoprim-sulfamethoxazole (Bactrim), Ciprofloxacin (Cipro), Clavulanic acid (Augmentin) are some of the antibiotic drugs which are used in the treatment of acute diverticulitis. Therefore, it has increased the demand for drugs in diverticulitis disease treatment. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.
Diverticulitis Disease Treatment Market
| Metrics | Details |
| Market CAGR | 7.7% |
| Segments Covered | By Pet Type, By Treatment, By Route of Administration, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Diverticulitis Disease Treatment Market Geographical Analysis
North America region holds the largest market share in the global diverticulitis disease treatment market
In 2021, North America accounted for the highest revenue share. The rising geriatric population, increasing prevalence of obesity and smoking, rising demand for technologically advanced treatment, and growing public awareness of health issues in the region are factors the market is expected to boost in the forecast period. For instance, Overeating and physical inactivity are the two most common causes of obesity. Obesity is influenced by genetics, metabolism, environment, behavior, and culture, among other factors. The U.S. adult obesity rate stands at 42.4 percent, the first time the national rate has passed the 40 percent mark and further evidence of the country's obesity crisis.
Moreover, being Overweight affects more than one-third of men (34.1%) and one-quarter of women (27.5%). Obesity affects nearly half of all adults (42.4%). (including severe obesity). Severe obesity affects about one in every eleven persons (9.2%). The percentage of overweight men (34.1%) is higher than overweight women (33.4%). (27.5 percent ). Demand for services from the Weight Loss Services business is predicted to rise as the prevalence of adult obesity rises. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Diverticulitis Disease Treatment Market Competitive Landscape
Major key players in the diverticulitis disease treatment market are Pfizer Inc., G.D. Searle LLC, Teva Pharmaceuticals USA, Inc., B. Braun Medical Inc., GlaxoSmithKline, Inc., Bayer HealthCare Pharmaceuticals Inc., Hoffmann-La Roche Inc., Hikma Pharmaceuticals USA Inc.
Pfizer Inc.:
Overview:
Pfizer Inc. is an American multinational pharmaceutical company. The company develops and produces medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. Its drugs and vaccines provide value for healthcare providers and patients through the treatment of diseases improvements in health wellness. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.
Product Portfolio:
Flagyl Oral Formulation(metronidazole oral formulation): Metronidazole Oral Suspension is indicated in the prophylaxis and treatment of infections in which anaerobic bacteria have been identified or are suspected as the pathogen.
Frequently Asked Questions
What is the Projected CAGR value of the Diverticulitis Disease Treatment Market?
Diverticulitis Disease Treatment Market is expected to grow at a CAGR of 7.7% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Diverticulitis Disease Treatment Market during 2022-2029
Which is the fastest growing region in the Diverticulitis Disease Treatment Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period
